60 Degrees Takes Dengue Treatments Forward Saying 'Vaccines Are An Imperfect Solution'
This article was originally published in Scrip
Executive Summary
60 Degrees Pharmaceuticals (60P) is launching a Phase II trial for its dengue fever candidates – aiming to develop treatments for those infected with the virus rather than a preventative measure.